• graybug


    • Technology from Johns Hopkins University’s Wilmer Eye Institute; co-founders are world renowned ophthalmology and micro particle formulation experts
    • company in preclinical development with superior extended release/durable formulations for ocular diseases
    • Co-investors: Maryland Venture Fund
  • orig3n


    • Technology from Kyoto University and Nobel-prize winning work of Shinya Yamanaka
    • Commercializing a personalized, regenerative medicine platform utilizing incudes pluripotent stem cells, or iPS cells
    • Co-investors:  Mountain Group Capital, KTB Ventures, Harris & Harris
  • Clearside Biomedical

    Clearside Biomedical

    • Technology from Georgia Tech and Emory, this clinical-stage ophthalmic pharmaceutical company is utilizing a proprietary, disruptive microinjection platform to deliver drugs via the suprachoroidal space for sight-threatening diseases
  • G1 Therapeutics, Inc.

    G1 Therapeutics, Inc.

    • Technology from UNC-Chapel Hill’s comprehensive cancer center, this clinical-stage company is built on a robust platform of potent,
      selective CDK4/6 inhibitors to protect bone marrow from chemotherapy and ionizing radiation
    • lysosomal

      Lysosomal Therapeutics Inc.

      • Technology from Mass General and Harvard, this pre-clinical biotech company is developing allosteric glucocerebrosidase activators to restore lysosomal function in human neurons for treatment of Gaucher’s and Parkinson’s Diseases
  • Coferon


    • Technology from Cornell University, this company is developing a novel chemistry platform focused on developing small molecule,
      self-assembling pharmacophore pairs to intervene at dicult intra-cellular protein targets
  • Kinodyn


    • Technology from UNC- Chapel Hill’s Department of Pharmacology, this company is developing a platform to discover innovative approaches to prevent cellular reprogramming, in hopes of making existing cancer treatments more effective
    • Hatteras seed investment in mid-2014, Series A planned for 2015
  • Curoverse


    • Technology from Dr. George Church’s lab at Harvard, this company is developing an open-source platform to manage “big” genomic data; focused on increasing productivity and lowering costs for storing, organizing, analyzing and sharing NGS data
  • NeuroTronik, Inc.

    • This company is developing a neuromodulation device for patients suffering from heart failure; focused on the select stimulation of target nerves to impact hemodynamics, and deliver exceptional patient outcomes and positive healthcare economics